Clinical Trial Update: Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intralesional recombinant human epidermal growth factor (rhEGF) for efficacy and safety in diabetic foot ulcers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer

Drugs mentioned

• rhEGF (recombinant human epidermal growth factor)

Snippet

Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Conditions: Foot Ulcer, Diabetic, Epidermal Growth Factor | Phase 3 | Status: UNKNOWN